Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18142 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by James Lok. Institution: Institute of Liver Studies, King's College Hospital, London, UK. Major MEDLINE topics: Antiviral Agents. Cited 1 times so far (Crossref); 10 references.
Abstract (original language)
LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18174
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Institute of Liver Studies, King's College Hospital, London, UK.
ORCID profiles: James Lok
Cite
APA
Lok, J. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18142
Vancouver
Lok J. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18142
BibTeX
@article{Lok2024,
author = {Lok, James},
title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18142}
}
EUVIMED